Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Position Increased by Handelsbanken Fonder AB

Handelsbanken Fonder AB lifted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 12.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 23,815 shares of the biotechnology company’s stock after acquiring an additional 2,600 shares during the period. Handelsbanken Fonder AB’s holdings in Sarepta Therapeutics were worth $2,974,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. Mather Group LLC. purchased a new position in Sarepta Therapeutics during the 1st quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. boosted its position in shares of Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after buying an additional 125 shares during the period. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics during the second quarter valued at $31,000. New Covenant Trust Company N.A. acquired a new position in Sarepta Therapeutics during the first quarter valued at $32,000. Finally, GAMMA Investing LLC raised its position in Sarepta Therapeutics by 37.0% during the first quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 87 shares during the period. Institutional investors and hedge funds own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Bank of America increased their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a research report on Friday, June 21st. Cantor Fitzgerald reissued a “neutral” rating and set a $152.00 target price on shares of Sarepta Therapeutics in a research note on Friday, September 20th. Leerink Partners boosted their price target on shares of Sarepta Therapeutics from $165.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Citigroup cut their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Finally, UBS Group boosted their target price on Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $187.44.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Michael Andrew Chambers acquired 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The stock was bought at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now owns 284,034 shares of the company’s stock, valued at $38,003,749.20. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was acquired at an average price of $133.80 per share, for a total transaction of $4,955,684.40. Following the completion of the purchase, the director now owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Ian Michael Estepan sold 5,985 shares of the business’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the transaction, the chief financial officer now owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $119.72 on Wednesday. The company has a market capitalization of $11.32 billion, a PE ratio of 1,088.36 and a beta of 0.82. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. Sarepta Therapeutics, Inc. has a one year low of $55.25 and a one year high of $173.25. The company’s fifty day moving average price is $131.50 and its 200 day moving average price is $132.66.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The company had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same period last year, the business posted ($0.27) earnings per share. The firm’s revenue was up 38.9% compared to the same quarter last year. As a group, analysts expect that Sarepta Therapeutics, Inc. will post 1.45 earnings per share for the current year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.